Compare · ABT vs AMLX
ABT vs AMLX
Side-by-side comparison of Abbott Laboratories (ABT) and Amylyx Pharmaceuticals Inc. (AMLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AMLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $187.45B, about 43.8x AMLX ($4.28B).
- AMLX has been more active in the news (16 items in the past 4 weeks vs 10 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 24 for AMLX).
- Company
- Abbott Laboratories
- Amylyx Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $187.45B
- $4.28B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 16
- Recent ratings
- 25
- 24
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest AMLX
- Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
- Director Firestone Karen exercised 50,000 shares at a strike of $3.40, increasing direct ownership by 75% to 116,900 units (SEC Form 4)
- Chief Financial Officer Frates James M was granted 22,807 shares, increasing direct ownership by 10% to 244,435 units (SEC Form 4)
- Co-Chief Executive Officer Klee Justin B. was granted 60,039 shares, increasing direct ownership by 2% to 3,643,520 units (SEC Form 4)
- Chief Legal Officer Mazzariello Gina was granted 21,284 shares, increasing direct ownership by 12% to 200,374 units (SEC Form 4)
- Co-Chief Executive Officer Cohen Joshua B was granted 60,039 shares, increasing direct ownership by 2% to 3,643,587 units (SEC Form 4)
- Chief Medical Officer Bedrosian Camille L was granted 22,807 shares, increasing direct ownership by 9% to 288,092 units (SEC Form 4)
- SEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.
- SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.
- Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock